XXXX for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.

@entity1 @entity23022 @entity63 @entity1397 @entity117 @entity8729 @entity715 @entity857
BACKGROUND: @entity1397 is administered to prevent stent @entity715 ; however, the uniformity of platelet inhibition after treatment and the influence of pretreatment reactivity on drug response have not been described. METHODS AND RESULTS: Platelet aggregation (5 and 20 micromol/L @entity857 ), the activation of glycoprotein IIb/IIIa ( @entity23022 antibody), and the expression of @entity8729 were measured in @entity1 undergoing elective coronary stenting (n=96) at baseline and at 2 hours, 24 hours, 5 days, and 30 days after stenting. All @entity1 received @entity117 (325 mg). @entity1397 (300 mg) was administered in the catheterization laboratory and followed by 75 mg daily. There was marked interindividual variability in drug response as measured by all markers that showed a normal distribution. Resistance, defined as baseline aggregation (%) minus posttreatment aggregation (%) < or =10% by 5 micromol/L @entity857 , was present in 31% and 15% of @entity1 at 5 and 30 days, respectively. @entity1 with the highest pretreatment platelet reactivity remained the most reactive at 24 hours after treatment (P<0.0001). CONCLUSIONS: Interindividual variability in the platelet inhibitory response from @entity1397 occurs in @entity1 undergoing elective coronary stenting. @entity1 with high pretreatment reactivity are least protected. Alternative pharmacological strategies and the association of adverse @entity63 events should be investigated in these @entity1 .
